Rhythm Pharmaceuticals, Inc. (RYTM) Stock Price & Analysis
Rhythm Pharmaceuticals, Inc. (RYTM) fell 0.55% to USD 102.1 as of July 25, 2026 at 03:49 UTC, according to Nexqual real-time market data.
RYTM last closed at USD 102.66; the session ranged USD 101.49–104.86 on volume of 435,783 shares. Market capitalization is $7.00B, with a 52-week range of USD 74.5–122.2 (NGM). Source: Nexqual, July 25, 2026 at 03:49 UTC.
Key Statistics (as of July 25, 2026 at 03:49 UTC)
| Price | USD 102.1 |
|---|---|
| Change | ▼ 0.55% (down) |
| Previous Close | USD 102.66 |
| Open | USD 103.92 |
| Day Range | USD 101.49 – 104.86 |
| 52-Week Range | USD 74.5 – 122.2 |
| Volume | 435,783 shares |
| Market Cap | $7.00B |
| Exchange | NGM |
Technical Analysis (RYTM)
Nexqual's technical model rates RYTM "BUY" based on 4 bullish and 2 bearish signals across 125 daily candles, as of July 25, 2026 at 03:49 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 48.53 (neutral) |
| vs SMA50 | Above (USD 98.49) |
| MACD | 1.16 (positive) |
Analyst Ratings (RYTM)
Wall Street analysts rate RYTM "Strong Buy" based on 14 analysts, with a mean price target of USD 138.36 (range USD 105–155), per Nexqual as of July 25, 2026 at 03:49 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 14 |
| Mean Target | USD 138.36 |
| High Target | USD 155 |
| Low Target | USD 105 |
| Buy / Hold / Sell | 14 / 1 / 0 |
Earnings (RYTM)
| Next Earnings Date | 2026-08-04 |
|---|---|
| EPS Estimate | USD -0.84 |
| Revenue Estimate | $67.35M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.83 vs est -0.86 ▲ beat |
| 2025-12-31 | USD -0.73 vs est -0.78 ▲ beat |
| 2025-09-30 | USD -0.82 vs est -0.73 ▼ miss |
| 2025-06-30 | USD -0.75 vs est -0.67 ▼ miss |
Source: Nexqual, July 25, 2026 at 03:49 UTC.
Financials & Fundamentals (RYTM)
| Total Revenue | $217.16M |
|---|---|
| Revenue Growth (YoY) | +83.80% |
| Gross Margin | +89.41% |
| Operating Margin | -87.11% |
| Profit Margin | -93.33% |
| ROE | -101.16% |
| Debt / Equity | 47.26 |
| Current Ratio | 4.17 |
| Total Cash | $340.62M |
| Total Debt | $112.31M |
| Free Cash Flow | $-150.68M |
Source: Nexqual, July 25, 2026 at 03:49 UTC.
Financial Health Score (RYTM)
Nexqual rates Rhythm Pharmaceuticals, Inc.'s overall financial health "Mixed" across five dimensions, as of July 25, 2026 at 03:49 UTC.
| Growth | Strong — Revenue +46% YoY (annual) |
|---|---|
| Profitability | Solid — Gross margin 89%, operating -87% |
| Balance Sheet | Strong — $341M cash vs $112M debt, net cash position |
| Cash Flow | Weak — FCF negative: -$151M, burning cash |
| Efficiency | Critical — ROE -101%, ROA -29.8% |
Ownership (RYTM)
| Insider Ownership | +0.77% |
|---|---|
| Institutional Ownership | +110.25% |
| Shares Outstanding | 68.59M |
| Float | 55.67M |
| Short % of Float | +14.20% |
Source: Nexqual, July 25, 2026 at 03:49 UTC.
Leadership (RYTM)
Rhythm Pharmaceuticals, Inc. is led by David P. Meeker (age 71), Chairman, President & CEO, per Nexqual as of July 25, 2026 at 03:49 UTC.
| Chairman, President & CEO | David P. Meeker (age 71) |
|---|---|
| CFO & Treasurer | Hunter C. Smith (age 56) |
| Chief Scientific Officer | Alastair Garfield (age 45) |
| Vice President of Sales & Marketing | Sarah Ryan |
Major Backers & Investors (RYTM)
Notable institutional backers of Rhythm Pharmaceuticals, Inc. include RA Capital Management, L.P., Baker Bros. Advisors, LP, Primecap Management Company, according to Nexqual as of July 25, 2026 at 03:49 UTC.
Active Investors
| Investor | Stake |
|---|---|
| RA Capital Management, L.P. | 9.73% |
| Baker Bros. Advisors, LP | 8.18% |
| Primecap Management Company | 4.99% |
| PRIMECAP Odyssey Funds-PRIMECAP Odyssey Aggressive Growth Fund | 4.7% |
| Perceptive Advisors Llc | 3.46% |
| Goldman Sachs | 2.87% |
| Westfield Capital Management Co LP | 2.81% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 16.52% |
| BlackRock | 10.95% |
| State Street | 5% |
Source: Nexqual, July 25, 2026 at 03:49 UTC.
From Rhythm Pharmaceuticals, Inc.'s Latest SEC 10-K Filing (filed 2026-02-26)
Key Strengths & Strategy (as disclosed to the SEC)
- We have established a strong global foundation with IMCIVREE (setmelanotide), which has achieved regulatory approvals and marketing authorization, reimbursed access or named patient sales in more than 25 countries, including the United States, the European Union and the United Kingdom.
- The EMA confirmed validation of our Type II variation submission to the Marketing Authorization Application (MAA) for setmelanotide for the same indication.
- These estimates are based on our patient identification efforts in the United States and Europe and our proprietary genetic sequencing data, as well as our belief that BBS, like most rare diseases, is underdiagnosed.
- We also expect EMANATE results, in combination with results from our completed DAYBREAK trial, to advance our understanding of which genetic variants are associated with loss of function and to inform on our approach to future clinical development.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| CRNX | Crinetics Pharmaceuticals, Inc. | USD 83.73 | ▲ 0.01% |
| KRYS | Krystal Biotech, Inc. | USD 335.19 | ▼ 0.48% |
| PTGX | Protagonist Therapeutics, Inc. | USD 136.11 | ▲ 0.49% |
| ANAB | AnaptysBio, Inc. | USD 54.15 | ▲ 2.93% |
| MIRM | Mirum Pharmaceuticals, Inc. | USD 113.03 | ▼ 1.27% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 03:49 UTC. This page is informational and not investment advice.